Indolinyl-sulfonamide inhibitors of tankyrase and methods of use thereof
The present disclosure provides compounds that may be useful for inhibiting the Tankyrase enzyme. In some aspects, these compounds are useful in the treatment of a disease or disorder related to the misregulation of Tankyrase enzyme such as cancer, degenerative diseases, or fibrotic diseases. Also provided herein are compounds may also be used to prevent the elongation of the telomere in a cell.
1. A method of inhibiting a Tankyrase enzyme in a cell comprising administering to the cell an amount sufficient to cause inhibition of a compound of the formula:
wherein:
R 1 is hydrogen, alkyl (C≤8) , substituted alkyl (C≤8) , acyl (C≤8) , or substituted acyl (C≤8) ;
R 2 , R 3 , and R 4 are each independently selected from hydrogen, amino, cyano, halo, hydroxy, nitro, alkyl (C≤8) , substituted alkyl (C≤8) , alkoxy (C≤8) , substituted alkoxy (C≤8) , alkylamino (C≤8) , substituted alkylamino (C≤8) , dialkylamino (C≤8) , substituted dialkylamino (C≤8) , amido (C≤8) , substituted amido (C≤8) , acyl (C≤8) , or substituted acyl (C≤8) ;
n is 1, 2, 3, or 4;
A 1 and A 2 are each independently selected from —C(O)— or —S(O) 2 —;
x and y are each independently selected from 1, 2, 3, 4, or 5;
R 5 is hydrogen, alkyl (C≤8) , substituted alkyl (C≤8) , acyl (C≤8) , or substituted acyl (C≤8) ;
R 6 is aryl (C≤12) , heteroaryl (C≤12) , or a substituted version of either of these groups;
or a pharmaceutically acceptable salt thereof.
2. The method of claim 1 , wherein R 1 is acyl (C≤8) or substituted acyl (C≤8) .
3. The method of claim 1 , wherein n is 1 or 2.
4. The method of claim 1 , wherein R 2 is halo.
5. The method of claim 1 , wherein x and y are 1 or 2.
6. The method of claim 1 , wherein R 5 is alkyl (C≤8) or substituted alkyl (C≤8) .
7. The method of claim 1 , wherein R 6 is aryl (C≤12) or substituted aryl (C≤12) .
8. The method of claim 7 , wherein R 6 is tolyl.
9. The method of claim 7 , wherein R 6 is 3-methylphenyl.
10. The method of claim 1 , wherein the compound is further defined as:
or a pharmaceutically acceptable salt thereof.
11. The method of claim 1 , wherein the Tankyrase enzyme is Tankyrase 1.
12. The method of claim 1 , wherein the Tankyrase enzyme is Tankyrase 2.
13. The method of claim 1 further comprising adding one or more additional inhibitors of a Tankyrase enzyme.
14. A method of treating a disease or disorder associated with the misregulation of a Tankyrase enzyme in a patient comprising administering to the patient in need thereof a therapeutically effective amount of a compound or a pharmaceutical composition comprising a compound of the formula:
wherein:
R 1 is hydrogen, alkyl (C≤8) , substituted alkyl (C≤8) , acyl (C≤8) , or substituted acyl (C≤8) ;
R 2 , R 3 , and R 4 are each independently selected from hydrogen, amino, cyano, halo, hydroxy, nitro, alkyl (C≤8) , substituted alkyl (C≤8) , alkoxy (C≤8) , substituted alkoxy (C≤8) , alkylamino (C≤8) , substituted alkylamino (C≤8) , dialkylamino (C≤8) , substituted dialkylamino (C≤8) , amido (C≤8) , substituted amido (C≤8) , acyl (C≤8) , or substituted acyl (C≤8) ;
n is 1, 2, 3, or 4;
A 1 and A 2 are each independently selected from —C(O)— or —S(O) 2 —;
x and y are each independently selected from 1, 2, 3, 4, or 5;
R 5 is hydrogen, alkyl (C≤8) , substituted alkyl (C≤8) , acyl (C≤8) , or substituted acyl (C≤8) ;
R 6 is aryl (C≤12) , heteroaryl (C≤12) , or a substituted version of either of these groups;
or a pharmaceutically acceptable salt thereof.
15. The method of claim 14 , wherein the compound is further defined as:
or a pharmaceutically acceptable salt thereof.
16. A pharmaceutical composition comprising an excipient or a pharmaceutically acceptable carrier and a compound of the formula:
wherein:
R 1 is hydrogen, alkyl (C≤8) , substituted alkyl (C≤8) , acyl (C≤8) , or substituted acyl (C≤8) ;
R 2 , R 3 , and R 4 are each independently selected from hydrogen, amino, cyano, halo, hydroxy, nitro, alkyl (C≤8) , substituted alkyl (C≤8) , alkoxy (C≤8) , substituted alkoxy (C≤8) , alkylamino (C≤8) , substituted alkylamino (C≤8) , dialkylamino (C≤8) , substituted dialkylamino (C≤8) , amido (C≤8) , substituted amido (C≤8) , acyl (C≤8) , or substituted acyl (C≤8) ;
n is 1, 2, 3, or 4;
A 1 and A 2 are each independently selected from —C(O)— or —S(O) 2 —;
x and y are each independently selected from 1, 2, 3, 4, or 5;
R 5 is hydrogen, alkyl (C≤8) , substituted alkyl (C≤8) , acyl (C≤8) , or substituted acyl (C≤8) ;
R 6 is aryl (C≤12) , heteroaryl (C≤12) , or a substituted version of either of these groups;
or a pharmaceutically acceptable salt thereof.
17. The pharmaceutical composition of claim 16 , wherein the compound is further defined as:
or a pharmaceutically acceptable salt thereof.